EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluating [225Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice

Marco F Taddio iD, Suraj Doshi, Marwan Masri, Pauline Jeanjean, Firas Hikmat, Alana Gerlach, Lea Nyiranshuti, Ethan W Rosser, Dorthe Schaue, Elie Besserer-Offroy, Giuseppe Carlucci, Caius G Radu und 3 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2024-11 · 51 (13) · 4026-4037

DOI: 10.1007/s00259-024-06809-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 15.07.2024. Verfasst von Marco F Taddio und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. mtaddio@protonmail.com. Hauptthemen laut MEDLINE: Sarcoma, Endopeptidases. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Prostate Cancer Foundation, Jonsson Comprehensive Cancer Center, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose Fibroblast Activation Protein (FAP) is an emerging theranostic target that is highly expressed on cancer-associated fibroblasts and on certain tumor cells including sarcoma. We investigated the anti-tumor efficacy of [ 225 Ac]Ac-FAPI-46 as monotherapy or in combination with immune checkpoint blockade (ICB) in immunocompetent murine models of sarcoma sensitive or resistant to ICB. Methods [ 68 Ga]Ga- and [ 225 Ac]Ac-FAPI-46 were tested in subcutaneous FAP+ FSA fibrosarcoma bearing C3H/Sed/Kam mice. The efficacy of up to three cycles of 60 kBq [ 225 Ac]Ac-FAPI-46 was evaluated as monotherapy and in combination with an anti-PD-1 antibody. Efficacy of [ 225 Ac]Ac-FAPI-46 and/or ICB was further compared in FAP-overexpressing FSA (FSA-F) tumors that were sensitive to ICB or rendered ICB-resistant by tumor-induction in the presence of Abatacept. Results [ 225 Ac]Ac-FAPI-46 was well tolerated up to 3 × 60 kBq but had minimal effect on FSA tumor growth. The combination of three cycles [ 225 Ac]Ac-FAPI-46 and ICB resulted in growth delay in 55% of mice (6/11) and partial tumor regression in 18% (2/11) of mice. In FSA-F tumors with FAP overexpression, both [ 225 Ac]Ac-FAPI-46 and ICB were effective without additional benefits from the combination. In locally immunosuppressed and ICB resistant FAP-F tumors, however, [ 225 Ac]Ac-FAPI-46 restored responsiveness to ICB, resulting in significant tumor regression and tumor-free survival of 56% of mice in the combination group up to 60 days post treatment. Conclusion [ 225 Ac]Ac-FAPI-46 efficacy is correlated with tumoral FAP expression levels and can restore responsiveness to PD-1 ICB. These data illustrate that careful patient selection based on target expression and rationally designed combination therapies are critically important to maximize the therapeutic impact of FAP-targeting radioligands.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcomaEndopeptidasesAnimalsMiceActiniumGelatinasesMembrane ProteinsCell Line, TumorSerine EndopeptidasesFemaleImmune Checkpoint InhibitorsFibroblast Activation Protein Alpha

Stichwörter der Autor:innen

Actinium-225FAPI-46Fibroblast activation proteinImmune checkpoint blockadeSarcomaTheranostic

Substanzen

EndopeptidasesActiniumGelatinasesMembrane ProteinsSerine EndopeptidasesImmune Checkpoint InhibitorsFibroblast Activation Protein AlphaActinium-225

Autor:innen und Institutionen

  • Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. mtaddio@protonmail.com.
  • Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.

ORCID-Profile: Marco F Taddio

Förderung

  • Prostate Cancer Foundation
  • Jonsson Comprehensive Cancer Center
  • NCI NIH HHS
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Taddio, M. F., Doshi, S., Masri, M., Jeanjean, P., Hikmat, F., Gerlach, A., Nyiranshuti, L., Rosser, E. W., Schaue, D., Besserer-Offroy, E., Carlucci, G., Radu, C. G., Czernin, J., Lückerath, K., & Mona, C. E. (2024). Evaluating [225Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice. European Journal of Nuclear Medicine and Molecular Imaging, 51(13), 4026-4037. https://doi.org/10.1007/s00259-024-06809-4

Vancouver

Taddio MF, Doshi S, Masri M, Jeanjean P, Hikmat F, Gerlach A, et al. Evaluating [225Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice. European Journal of Nuclear Medicine and Molecular Imaging. 2024;51(13):4026-4037. doi:10.1007/s00259-024-06809-4

BibTeX
@article{Taddio2024,
  author = {Taddio, Marco F and Doshi, Suraj and Masri, Marwan and Jeanjean, Pauline and Hikmat, Firas and Gerlach, Alana and Nyiranshuti, Lea and Rosser, Ethan W and Schaue, Dorthe and Besserer-Offroy, Elie and Carlucci, Giuseppe and Radu, Caius G and Czernin, Johannes and Lückerath, Katharina and Mona, Christine E},
  title = {Evaluating [225Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  volume = {51},
  number = {13},
  pages = {4026--4037},
  doi = {10.1007/s00259-024-06809-4}
}
Kostenlos starten →